Recent evidence has suggested that pancreatic islets isolated from rats synthesize 1,2-diacyl-sn-glycerol (DAG) de novo from glucose and that this process may constitute the longsought link between the metabolism of glucose and the induction of insulin secretion. The cell-permeant diacylglycerol 1-oleoyl-2-acetyl-sn-glycerol (200 ;&M) has been found here to amplify both the first and second phases of insulin secretion from perifused human islets. Measurements of the mass of endogenous DAG in human pancreatic islets by enzymatic and by mass spectrometric methods indicate that levels of 200 I&M may be achieved under physiologic conditions. Conversion of 1'4Cjglucose to I'4CIDAG has been demonstrated here to occur within 60 s of exposure of rat and human islets to stimulatory concentrations of glucose. This process has been found to be a quantitatively minor contributor to the total islet DAG mass after acute stimulation with glucose, however, and glucose has been found not to induce a rise in total islet DAG content within 20 min of induction of insulin secretion. In contrast to the case with rodent islets, two pharmacologic inhibitors of DAG-induced activation of protein kinase C (staurosporine and sphingosine) have been found not to influence glucose-induced insulin secretion from isolated human islets. These findings indicate that de novo synthesis of DAG from glucose does not participate in acute signal-response coupling in islets. (J. Clin. Invest. 1990. 85:482-490.) diacylglycerol -insulin * pancreatic islets
Introduction
The beta cells of pancreatic islets maintain the blood glucose concentration within a narrow range by modulating their insulin secretory rate in response to the glucose levels in blood (1) . This glucose sensor function appears to be intrinsic to islets, since islets isolated from human or rodent pancreata retain the ability to augment their insulin secretory rate in response to increases in the glucose concentration in the medium bathing them (2) (3) (4) (5) (6) (7) (8) (9) . Some insulin secretagogues, such as muscarinic agonists, induce insulin secretion via interaction with a beta cell plasma membrane receptor (5, 8) . Glucose and ical mechanisms whereby islet glucose recognition is coupled to insulin secretion have been intensively studied because the disease type II diabetes mellitus is characterized by a relatively selective defect in glucose-induced insulin secretion despite nearly normal secretory responses to some other insulin secretagogues (10) .
Recent interest has focused on the possibility that 1,2-diacyl-sn-glycerol (DAG)' synthesized de novo from glucose in beta cells might constitute the metabolic signal derived from glucose that initiates insulin secretion, possibly by activation ofprotein kinase C (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . This hypothesis is based primarily on observations with rat islets, including the facts that exogenous diacylglycerol (13, 14) and phorbol esters (15) augment insulin secretion, that glucose induces the accumulation of a palmitate-rich 1,2-diacyl-sn-glycerol in islets (12, 13) , and that pharmacologic inhibitors of protein kinase C suppress glucose-induced insulin secretion (16, 17 (18) , which is one of the triose phosphates (22). The attractiveness of the diacylglycerol hypothesis of insulin secretion is enhanced by the fact that all known carbohydrate insulin secretagogues, including glucose and mannose, are converted by islets to the triose phosphates (4, 6) . The closely related compounds lactate and pyruvate are not converted to triose phosphates by islets and do not induce insulin secretion, although these compounds are readily oxidized by islets (6) .
To evaluate this hypothesis further, we have determined the quantitative significance and time course of diacylglycerol accumulation via de novo synthesis from glucose in rat and in human islets, the content of palmitate and other fatty acyl substituents in human islet diacylglycerol under basal conditions and after stimulation with glucose, and the influence of exogenous diacylglycerol and of pharmacologic inhibitors of protein kinase C on insulin secretion from human islets. 
Methods

Materials
Islet preparation
Isolation and culture ofrat islets. Islets were isolated aseptically from male Sprague-Dawley rats, fed ad lib. as described elsewhere by a procedure involving pancreatic excision, collagenase digestion, and discontinuous Ficoll density gradient separation (23, 24) . This procedure typically yielded 400 islets/rat. In a typical experiment, islets were isolated from 30 rats. The pooled islets (-12,000 islets) were then cultured overnight in four Petri dishes (-3,000) with 2.5 ml of complete CMRL-1066 at 240C under an atmosphere of 95% air/5% CO2.
Islets cultured in this way exhibit a robust insulin secretory response and enhanced generation of some lipid mediators in response to glucose (23) .
Isolation and culture of human islets. Pancreases were removed from four separate life-supported cadavers when other organs were obtained for transplantation. Islets were isolated from the pancreas by methods described elsewhere (25) and were cultured for 3-7 d at 240C and for 24 h at 370C just before use under an atmosphere of 95% air/5% CO2 in tissue culture medium CMRL-1066 containing 10% fetal bovine serum, penicillin (100 U/ml), glutamine (2 mM), and Hepes (25 mM) at pH 7.4. Measurement offatty acyl composition ofDAG Incubation ofhuman islets. For mass measurement experiments, isolated human islets (-12,000) were washed three times in HepesKrebs-3 mM glucose medium, counted (3,000/tube) into 16 X 100 mm acid-washed silanized borosilicate tubes, and preincubated 30 min with shaking in 0.1 ml of Hepes-Krebs-3 mM glucose (25 mM Hepes, pH 7.4, 115 mM NaCl, 24 mM NaHCO3, 5 mM KC1, 2.5 mM CaCl2, 1 mM MgCI2, and 0.1% fatty acid free bovine serum albumin) at 37°C under an atmosphere of 95% air/5% CO2. The medium was then removed from each tube and replaced with 0.1 ml of fresh HepesKrebs medium supplemented with 17 mM glucose prewarmed to 37°C. The tubes were then incubated with shaking for 5 min at 37°C under an atmosphere of 95% air/5% CO2. At the end of this period 1 ml of ice-cold methanol was added. The tubes were then chilled for 15 min in a liquid N2 bath and stored at -70°C before extraction.
Extraction ofdiacylglycerol. Before extraction, tubes for the mass measurement experiments received 0.25 ml of an internal standard solution (100 ng of 1,2-dierucoyl-sn-glycerol) prepared from 1,2-diacyl-sn-glycerol-phosphocholine with Bacillus cereus phospholipase C by methods described elsewhere (13). To each tube was then added 1.25 ml of solvent A. (Solvent A is chloroform/methanol, 1:2, vol/vol.)
The tubes were then sonicated (30 min, 4C) and vortexed. CHC13 (0.66 ml) and then H20 (0.66 ml) were added, and the tubes were centrifuged (3 min in a table-top centrifuge). The lower (organic) layer was transferred (acid-washed silanized Pasteur pipette) to an acidwashed, silanized 3.5 ml glass vial. The remaining aqueous phase was re-extracted three times with CHC13 (1 ml). These extracts were combined with the previous organic phase, concentrated under N2, and reconstituted in heptane (0.25 ml).
HPLC analysis of DAG. Extracted samples were analyzed by HPLC on a APorasil column (3.9 mm X 30 cm; Waters Associates, Milford, MA) as described previously (13) . Solvent was delivered at a rate of 2 ml/min with the following program: solvent B (hexane/isopropanol/acetic acid, 100:1:0.01, vol/vol/vol) for 13 min, a linear gradient over 5 min to solvent C (hexane/isopropanol/acetic acid, 100:10:0.01, vol/vol/vol), and then solvent C for 7 min. The retention volumes of standard glycerolipids were as follows: triacylglycerol (5 ml); 1,3-diacyl-sn-glycerol (13 ml); DAG (21 ml); and monoacylglycerol (50 ml). A 2,3-diacylglycerol is the enantiomer of the corresponding 1,2-diacylglycerol, and therefore these compounds cannot be separated by HPLC or other physical or chemical means unless a second optical center is introduced into the system (e.g., use ofa chiral derivatizing reagent, a chiral column, or an enzyme) (26) . Phospholipids did not elute in this system, and were retained on a guard column (13) , which was changed after every 15 runs. Islet-derived DAG was collected into an acid-washed, silanized 7-ml glass vial, concentrated under N2, and stored in 0.5 ml of heptane before hydrolysis.
Hydrolysis ofDAG tofreefatty acids. Samples were concentrated to dryness, saponified with 0.2 N NaOH, and extracted into CH2Cl2 as described previously ( 13) .
Pentafluorobenzyl esterification offreefatty acids. Fatty acids were converted to pentafluorobenzyl esters with pentafluorobenzyl bromide as described previously (13) and reconstituted in heptane.
Gas chromatography-mass spectrometry. Gas chromatography (GC) was performed on a 5840 gas chromatograph interfaced with a 5988 mass spectrometer (both from Hewlett-Packard Corp., Palo Alto, CA) operated in the negative ion chemical ionization mode (methane source pressure 1 Torr) using a Hewlett-Packard Ultraperformance capillary column (8 m length, crosslinked methylsilicone, i.d. 0.31 mm, film thickness 0.17 Mm) operated with a Grob-type injector in the splitless mode as previously described (13) . The GC oven temperature was programmed from 850 to 200°C at a rate of 30°C/min starting 0.5 min after injection. Selected ions were monitored that corresponded to the m/z [M-18 1 ] ions of the fatty acid pentafluorobenzyl ester derivatives. Peak identity was assigned by the mass ofthe monitored ions and by retention times relative to standard fatty acid pentafluorobenzyl esters. The fatty acid pentafluorobenzyl esters were quantitated relative to erucoylpentafluorobenzyl ester (C22:1 internal standard). Before each set of analyses, a standard curve for each fatty acid pentafluorobenzyl ester was generated. Blank samples derived from incubation medium containing no islets were processed in parallel with islet-derived samples in all experiments, and the observed blank signal was subtracted from the signal of islet-derived samples. Background amounts of fatty acids in blank tubes were 66±21 pmol of myristate, 264±66 pmol of palmitate, 200±27 pmol of stearate, 79±11 pmol of oleate, 1±2 pmol of linoleate, and 3±2 pmol ofarachidonate (n = 7). Higher blanks were avoided by strictly excluding plasticware from all phases of processing; employing only acid-washed, silanized glassware (including pasteur pipettes); by wearing disposable gloves throughout sample preparation; and by screening solvents and reagents for fatty acid content and employing only those with minimal amounts. Since the total fatty acid background was 600 pmol and the fatty acyl content of islet DAG was -1 pmol/islet, 3,000 islets were employed per condition for diacylglycerol fatty acyl mass measurements to achieve an islet signal fivefold or greater above background.
Measurement ofde novo synthesis ofDAGfrom glucose Incorporation of ['4C]glucose into islet DAG. Isolated rat or human islets were randomly counted (500/tube) into siliconized 13 X 100 borosilicate tubes, preincubated 30 min at 370C in 0.1 ml of HepesKrebs-3 mM glucose medium under an atmosphere of 95% air/5% CO2. Incubation was initiated by the further addition of 0.1 ml of Hepes-Krebs medium containing ['4C]glucose to yield a final concentration of 3 or 17 mM glucose with a final specific activity of 58.3 or 11.7 mCi/mmol, respectively. The incubation was continued for 15 s to 2 h at 370C in a shaking water bath under an atmosphere of 95% air/5% CO2 and terminated by the addition of 1 ml of methanol (previously chilled in an isopropanol/dry ice bath) and 0.1 ml ofa 300-mM glucose solution. The tubes were then immersed in a liquid N2 bath for 15 min. In some experiments, islets (1,000/dish) were incubated 24 or 48 h in 1 ml of complete CMRL-1066 supplemented with 5.5 or 17 mM [14C]glucose (final specific activity of 32.2 or 10.7 mCi/mmol, respectively).
Measurement of "'C-labeled islet 1,2-diacyl-sn-glycerol. Before extraction, 0.05 ml of internal standard (30-50,000 cpm of 1-stearoyl-2-[3H8]-arachidonyl-sn-glycerol in heptane) was added to each tube. Extraction of DAG was performed essentially as described above with chloroform/methanol into 10 ml borosilicate silanized conical tubes. The organic phase from the extraction was evaporated under N2 and reconstituted in 0.5 ml of chloroform. Half the sample was then transferred into a clean 10-ml borosilicate silanized conical tube and measured for DAG mass by the enzymatic assay described below. The remaining half of the sample received 10 gg each of oleic acid, monoolein, diolein, and triolein to aid in recovery, and was washed three times with 1 ml of H20. The organic phase was concentrated with 0.5 ml of chloroform/methanol (95:5, vol/vol), evaporated under N2, reconstituted in 0.05 ml of diethyl ether, and applied to a 20 X 20 cm TLC plate (Analtech silica gel G channeled plate). The plate was developed in solvent F (toluene/diethyl ether/ethanol, 35:10: 1, vol/vol/vol). Standard unlabeled mono-, di-, and triolein standards were run as controls and were visualized with 12 vapor. The spots corresponding to 1,2-diacyl-sn-glycerol were scraped into 20 ml borosilicate scintillation vials. Diethyl ether (0.5 ml) was added (30 min), followed by liquid scintillation cocktail (10 ml (27) . Several major modifications were incorporated into the original method (27) (20 ug) were added to each tube as carriers. This was followed by addition of 1 M NaCl (0.75 ml), vortexing (1 min), addition of CHC13 (1 ml), addition of 1 M NaCl (1 ml) and vortexing (1 min) . Samples were then centrifuged (5 m-, 800 g), and the upper aqueous phase was discarded. The lower organic phase was washed twice with 1% perchloric acid (2 ml). These acid aqueous washes were discarded after centrifugation. The lower (organic phase) was evaporated under N2, concentrated with 0. 
Measurement ofinsulin secretion
Islet perifusion. 300 isolated human islets were placed in each chamber of a dual or quadruple chamber perifusion apparatus perifused with Hepes-Krebs-3 mM glucose for 30 min at 370C as described (28, 29 ). The glucose concentration was then increased to 8 mM in both chambers, and 200MgM of l-oleoyl-2-acetyl-sn-glycerol in 0.4% DMSO was simultaneously added to the medium of the experimental but not the control chamber. The insulin content of aliquots of the perifusion effluent was measured by radioimmunoassay (23) . Insulin secretion from islets perifused first with 3 mM glucose and then with 28 mM glucose in the absence of OAG was determined in a similar manner.
Insulin secretion during static incubations. Isolated human islets were randomly counted (30/tube) into 10 X 75 mm borosilicate tubes and preincubated for 30 min at 37°C with shaking in 0.2 ml of HepesKrebs-3 mM glucose media under an atmosphere of 95% air/5% CO2. The medium was then removed from each tube and replaced with fresh medium (0.2 ml) supplemented with the appropriate agonist. Islets were then incubated with shaking at 37°C for varied time periods. At the end of the incubation, the supernatant was removed and placed on ice. Serial dilutions were prepared and stored at -20°C before determination of their insulin content by radioimmunoassay (23) .
Measurement ofprotein kinase C activity
Isolated human islets (10-16,000) were homogenized in 0.35 to 0.6 ml of ice-cold TES buffer (25 mM TES-NaOH pH 7.4, 1 mM EGTA, 0.5 mM DTT, 1 mM phenylmethane sulfonylfluoride, 100 ,g/ml leupeptin) using a Dounce (Teflon/glass) homogenizer (13 passes (17) . Protein kinase C activity was calculated after subtracting the basal activity reflected by 32Pi-incorporation into histone in the presence of Ca2" and absence of phosphatidylserine and diolein.
Results
Influence ofexogenous diacylglycerol on insulin secretionfrom human islets. Isolated human pancreatic islets perifused with medium containing 3 mM glucose for 30 min exhibited a basal insulin secretory rate of 0.1 U/islet per min as illustrated in Fig. 1 . Increasing the medium glucose concentration to 8 mM resulted in a brisk first phase of insulin secretion with a mean peak secretory rate of 0.55±0.23 RU/islet per min. A maximal mean glucose-induced insulin secretory rate of 1.27 uU/islet per min was achieved with 28 mM glucose. The second, sustained phase of insulin secretion in response to 8 mM glucose was 0.23±0.09 RU/islet per min. This was similar to the corresponding second phase secretory rate with 28 mM glucose and OAG plus 8 mM glucose was essentially equivalent to that achieved with a maximally stimulatory concentration of glucose (28 mM), and the second phase response was 3.2-fold greater than that induced by glucose alone. OAG did not induce insulin secretion from isolated islets incubated in medium containing either 0 or 3 mM glucose (not shown). These experiments indicate that exogenous diacylglycerol amplifies the insulin secretory response to glucose by isolated human pancreatic islets, as has previously been reported for rodent islets (13, 14) .
Endogenous DAG in human islets. To determine the quantity and fatty acyl substituents of any endogenous DAG in isolated human pancreatic islets, neutral lipids were extracted from the islets in the presence of an internal standard diacylglycerol (1,2-dierucoyl-sn-glycerol). The diacylglycerols in the extract were then isolated by HPLC, saponified to their constituent fatty acids, converted to their pentafluorbenzyl ester (PFBE) derivatives, and analyzed by GC negative ionchemical ionization (NICI) mass spectrometry (MS). The identity of endogenous fatty acyl substituents of human islet DAG was determined by GC retention time and characteristic ions on MS, and the quantity of these materials was determined relative to the known amount of erucate (C22: 1) in the internal standard, as illustrated in Fig. 2 . Isolated human islets were found to contain clearly detectable amounts of DAG, and, as illustrated in Fig. 3 , this material contained the fatty acyl substituents palmitate, stearate, oleate, linoleate, and arachidonate in approximately equal abundance. This is, in general, similar to the fatty acyl composition of diacylglycerols isolated from rodent islets, except that the relative abundance of linoleate is substantially greater in the human material. The total quantity of saponifiable long-chain fatty acyl substituents in human islet DAG was -1.3 pmol/islet. This would correspond to a DAG mass of 0.65 pmol/islet because ofthe stoichiometry of 2 mol of fatty acyl moieties per mole of glycerol. If the islet intracellular volume is 3 nl (7), dividing the DAG mass by that volume yields a concentration of 216 AM. In principle, then, endogenous islet DAG levels may approximate the concentrations of exogenous diacylglycerol required to influence insulin secretion.
De novo synthesis of DAG from glucose in islets. When isolated islets were incubated with uniformly labeled [ (Fig. 4) Fig. 4, A and B) .
De novo synthesis of diacylglycerol did, however, continue to occur in a glucose concentration and time-dependent manner at longer incubation times. At a basal glucose concentration (3 mM), de novo synthesis of DAG from glucose was linear for at least 2 h with a rate of incorporation of glucose into DAG of 0.2 pmol glucose/nmol DAG/min (r = 0.984). This rate of incorporation increased to 0.4 pmol glucose/nmol DAG/min (r = 1.000) at the stimulatory glucose concentration of 17 mM (Fig. 4 C) .
The magnitude of de novo synthesis of DAG stimulated by glucose was similar in human and rat islets (Fig. 4 B) GC RETENTION TIME (min) though these experiments clearly demonstrated de novo synthesis of DAG from glucose by both rat and human islets, the contribution from this process to the total islet DAG mass was quite small during incubation times of 20 min or less (Fig. 4, A glucose and is unlikely to cause an increase in total islet DAG content on the time scale involved in stimulus secretion coupling. At much longer incubation times, however, de novo synthesis is a significant contributor to the total islet DAG content.
Enzymatic measurement of total islet DAG content. To measure the total islet content of DAG, a modification of the method of Preis et al. (27) Mod- ifications of the original procedure that were found necessary to achieve satisfactory measurements of the amounts of DAG in islets included: (a) a much longer period of sonication to achieve quantitative solubilization ofthe DAG; (b) preincubation of the diglyceride kinase with unlabeled ATP to reduce the blank value of the preparations; (c) addition of unlabeled phosphatidic acid as a carrier to reduce adsorptive losses oflow level samples; and (d) inclusion of l-stearoyl-2-[3H8]arachidonyl-sn-glycerol as an internal standard to correct for losses during extraction and chromatography and to improve the precision of the measurements. The 3H from the internal standard and the 32P from the reaction product were distinguished by dual channel liquid scintillation counting. Under these conditions, the blank value of the assay was 40 pmol and the precision was 7%. The assay was linear from 100 pmol to the low nanomolar range.
Effect of glucose on islet DAG content. Basal islet DAG content as measured by this enzymatic assay was -1 pmol/ islet, as illustrated in Fig. 5 A. Addition of B. cereus phospholipase C to suspensions of intact islets in incubation buffer resulted in a sevenfold rise in their DAG content (Fig. 5 A) . Increasing the glucose content of the incubation buffer in- duced an increase in insulin secretion that was clearly demonstrable by 2 min and continued to rise progressively at 5 and 10 min (Fig. 5 B) . Under these conditions, however, glucose did not influence the DAG content of rat islets at any time point between 15 s and 20 min (Fig. 5 C) . Glucose also failed to influence the DAG content ofhuman islets as measured by the enzymatic assay or by GC-NICI-MS quantitation of the DAG fatty acyl content (Fig. 5 D) . There was an excellent correspondence between the mass of DAG in human islets measured by the enzymatic assay (0.75 pmol/islet) and the fatty acyl content of the DAG measured by GC-NICI-MS (1.34 pmol/islet) in view of the expected 1:2 stoichiometry (Fig. 5  D) . Analysis of the individual fatty acyl substituents of DAG Figure 5 . Effect of glucose on the DAG content of rat and human islets. Isolated rat or human islets were incubated as described in Fig.  4 Effect ofstaurosporine and sphingosine on protein kinase C activity and glucose-induced insulin secretion from human islets. To explore the possibility that glucose might induce a local, but functionally important, increase in DAG in human islets, the influence of compounds that suppress the activation of protein kinase C by diacylglycerol was examined. We have previously demonstrated that staurosporine (30) completely inhibits rat islet protein kinase C at a concentration of 10 nM in cell-free systems and that, at a concentration of 100 nM, staurosporine suppresses both phorbol ester and glucose-induced insulin secretion from rat islets (17) . As shown in Fig. 6 A, staurosporine (100 nM) inhibits protein kinase C activity in human islets with a concentration dependence similar to that observed in rat islets. Staurosporine (100 nM) did not, however, significantly influence basal or glucose-induced insulin secretion from human islets (Fig. 6 B) . Similar results were obtained with a second protein kinase C inhibitor, sphingosine (31) . Sphingosine failed to inhibit basal or glucose-induced insulin secretion from human islets at any concentration from 25 uM (Fig. 6 C) to 100 ,uM (not shown).
Discussion
This study establishes that exogenous diacylglycerol amplifies glucose-induced insulin secretion from isolated human pan- (41) (42) (43) (44) (45) . Diacylglycerol accumulation and/or protein kinase C activation may also play an important role in the action on islets ofcertain noncarbohydrate insulin secretagogues, such as cholinergic agonists (8, 11, 46) .
